Transitional cell carcinoma (TCC) of the bladder represents the fifth most prevalent malignancy in Western populations, with peak incidence found in males of the 60-to 70-year-old age group (Davies, 1982) . TCCs arise from the specialised urinary epithelium (urothelium) and comprise >90% of all bladder tumours. TCCs are clinically classified by their degree of bladder wall invasion (Stage; Ta to T4; UICC, 1978) and their degree of de-differentiation (Grade; GI to G3) (reviewed by Mostofi et al., 1988) . Muscle-invasive tumours (T2, T3 and T4) are routinely treated using chemotherapy regimens based on the cytotoxic agents cisplatin, methotrexate, vinblastine and doxorubicin, with total response rates of 60% (30% complete) commonly observed in previously untreated patients (Harker et al., 1985; Sternberg et al., 1988) . However, a large proportion (approximately 40%) of bladder tumours do not respond to chemotherapy, and the reasons underlying this treatment failure remain to be elucidated. Molecular mechanisms that mediate cellular drug resistance may play a role in the differential responsiveness of individual bladder tumours to chemotherapy.
The multidrug resistance-associated protein (MRP) is a 190 kDa membrane phosphoglycoprotein belonging to the ATP-binding cassette family of transporter proteins, to which the transmembrane drug efflux pump, P-glycoprotein (encoded by the MDRJ gene), also belongs (Cole et al., 1992; Endicott and Ling, 1989) . However, while MRP shares many of the structural and functional features of Pglycoprotein, the two proteins share only 15% amino acid identity Almquist et al., 1995) . Since its cloning and identification from the doxorubicin-selected small-cell lung cancer (SCLC) cell line, H69/AR (Cole et al., 1992) , the degree of overexpression of the 6.5 kb MRP mRNA has been shown to correlate well with the multidrug Correspondence: J Lunec Received 30 May 1995; revised 10 August 1995; accepted 3 October 1995 resistance (MDR) phenotype of a number of doxorubicinselected cell lines of different origin that do not overexpress P-glycoprotein (P-gp), including H69/AR, GLC4/ADR (SCLC; Zaman et al., 1993) , HL60/ADR (acute myeloid leukaemia; Marsh et al., 1986) , HT1080/DR4 (fibrosarcoma; Slovak et al., 1993) , COR-L23/R (large-cell lung carcinoma; Barrand et al., 1994) and T24/ADM-2 (TCC of the bladder, Hasegawa et al., 1995) , with MRP overexpression widely associated with reduced intracellular drug accumulation.
Gene transfection studies Cole et al., 1994) have demonstrated that introduction of the full-length MRP cDNA into HeLa cells confers a typical MDR phenotype, displaying cross-resistance to the anthracyclines (doxorubicin, daunorubicin, epirubicin), vinca alkaloids (vincristine, vinblastine), VP16 and taxol, but not mitoxantrone, 9-alkyl anthracyclines or cisplatin. ATP-dependent reduced drug accumulation was also observed in these transfectants which, coupled with recent monoclonal antibodies studies demonstrating localisation of the MRP protein to the plasma membrane in MRP transfectants and overexpressing cells by Flens et al. (1994 and Almquist et al. (1995) , is highly suggestive of a role for MRP as an energy-dependent transmembrane drug efflux pump. Recent studies have suggested that in some cells, MRP may alternatively or in addition be involved in the intracellular sequestration and redistribution of drugs away from their site of action (Cole et al., 1992; Almquist et al., 1995) , and in the ATP-dependent transport of glutathione Sconjugates across the cell membrane, thus providing a potential role for MRP in the removal of glutathioneconjugated xenobiotics from the cell (Muller et al., 1994 .
Optimisation of the polymerase chain reaction Oligonucleotide primers that recognise the MRP and 18SrRNA cDNA sequences were selected using the computer program designed by Lowe et al. (1990) . These were (in 5' to 3' orientation); MRP, sense strand ACTCCAACGCTGACAT-TTACC and antisense strand AAGTAGCTCATGCTG-TGCG (residues 2545-2565 and 2674-2692 respectively; Cole et al., 1992) , and 18SrRNA, sense strand ATGCTCT-TAGCTGAGTGTCC and antisense strand AACTACGAC-GGTATCTGATC (residues 864-883 and 1154-1175 respectively; Gonzalez and Schmikel, 1986) . The MDR] primer sequences used were those previously described by Noonan et al. (1990) . The primers yielded PCR products of 148 bp (MRP), 167 bp (MDRJ) and 311 bp (18SrRNA), and optimal magnesium chloride concentrations of 1 mM, 2.5 mM and 1 mm were determined for each of the primer pairs respectively. MRP and MDR] primers were each shown to produce differentially sized PCR products when cDNA and genomic DNA were used as reaction templates, and thus distinguish and discriminate any contaminating genomic DNA present in cDNA stocks by virtue of their spanning an intronic region.
Determination of gene transcript levels Serial cDNA dilutions for each species of interest were simultaneously and independently amplified over 25 PCR cycles (94°C for 1 min, 56°C for 1 min, 72°C for 1 min) using otherwise fixed reaction conditions, followed by electrophoretic separation and quantitative analysis of the radiolabelled PCR products using a Phosphorimager (Molecular Dynamics), as previously described . A typical Phosphorimager image of the separated products is shown in Figure la . For each species, the amount of PCR product (incorporated radioactivity) was plotted against input cDNA dilution ( Figure Ib) . Regression analysis was performed on the points falling on the linear range of amplification for each species. The gene transcript level relative to that of a reference gene is essentially measured as the ratio of cDNA dilutions required to yield a given amount of PCR product on the linear portion of the product vs input cDNA curve (see Clifford et al., 1994) . MRP and MDRI mRNA levels measured relative to 18SrRNA were thus expressed as MRP/ 18SrRNA and MDRJ/18SrRNA ratios respectively. For each cDNA sample, at least three replicates of the assay were performed, and the results analysed to give a mean (± s.e.) ratio, which represents the relative mRNA levels of the target and reference genes for the RNA sample. Extensive validations of this technique with respect to sensitivity, reproducibility and PCR amplification efficiency have previously been reported .
Results MRP gene transcript levels in normal and TCC bladder samples MRP mRNA levels were determined in 24 previously untreated TCC (by stage; Ta, n=8; T1, n= 5; T2, n= 1, T3, n=9; T4, n= 1; and by grade; GI, n=4; G2, n=9; G3, n = 11) and 5 normal bladder samples. In addition, one testis sample and two white blood cell samples (tissues previously reported to express high levels of MRP mRNA (Cole et al., 1992) ) and cell lines with differential MRP mRNA levels (GLC4 and GLC4/ADR; Zaman et al., 1993) were also assayed as positive controls. Results are shown in Figure 2 . The mean standard error for repeat determinations (n > 3) on any given sample was 27%, based on all samples analysed (n = 40). MRP gene expression in human bladder cancer SC Clifford et al 662 no significant differences (t-test, P = 0.38) were found between pooled mean MRP mRNA levels in groups of progressing [1.5 (± 0.9) X 10-5, n=4] and non-progressing [2.1 (+ 1.3) x 10-5, n = 9] superficial bladder tumours (both mean ± s.e.).
MRP mRNA levels and the response to chemotherapy MRP mRNA levels varied over a 45-fold range (5.9 + 10-7 to 2.69 x 10-5) in patients proceeding to receive the CMV chemotherapy regimen (n = 6), and a 56-fold range (1.95 x lo-6 to 1.10 x 10-s) in patients receiving EPICM therapy (n = 4). Figure 4a demonstrates that in the limited number of patients investigated to date, no evidence was found to suggest an association between high pretreatment MRP mRNA levels and resistance to either chemotherapy regimen. Furthermore, it is notable that the patient with the highest tumour MRP mRNA levels had a partial response to the CMV regimen.
MRP mRNA levels following treatment by chemotherapy In four cases, MRP mRNA levels were determined in paired post chemotherapy samples taken 2-3 weeks following the end of chemotherapy from partially responding patients.
Results are summarised in Figure 4b . Three patients had marginally increased MRP mRNA levels following treatment (patient 1, 2.4-fold; patient 2, 1.6-fold; patient 4, 1.7-fold), however for only one of these (patient 1) was the difference of borderline significance (P = 0.075). None of the elevated post treatment levels observed exceeded the mean MRP mRNA level found in untreated tumours. The most striking difference was observed in patient 3, who had significantly reduced (26.6-fold, P=0.014) tumour MRP mRNA levels following treatment. Results therefore did not suggest any consistent overall difference between pre-and post-chemotherapy MRP mRNA levels for either regimen.
Correlations between mRNA levels of the MRP and MDR1 genes in untreated TCC samples MDRI mRNA levels were also determined in each of the untreated TCC samples analysed (n= 24), and were found to vary over a 32-fold range (low, 3 x 10-7; high, 9.52 x 10-6). No significant correlations were observed between MRP and MDR] mRNA levels in intreated TCC ( Figure 5 ; linear regression analysis, r2 = 0.002; log regression analysis, r= 0.162). These results provide no evidence to suggest coexpression or common regulation of the MDRJ and MRP genes in TCC of the bladder. . Given the similarity between the range and level of MRP mRNA expression in normal bladder and TCC samples, it would be of future interest to determine whether MRP mRNA levels found in individual tumours are indeed reflective of those found in the surrounding normal tissue by investigating multiple biopsies from the bladders of individual patients that are commonly taken for prognostic purposes. Little is currently known regarding the mechanisms of MRP gene regulation that underlie the variations in MRP mRNA levels observed between individual tumours. For in vitro selected MDR cell lines, gene amplification has been demonstrated to account at least partially for increased MRP gene expression in the majority of cell lines previously reported, however, in the absence of any chemotherapeutic selection pressure, this seems unlikely in untreated tumours. Zhu and Center (1994) In summary, this study reports a pilot investigation demonstrating extensive variation in the levels of MRP mRNA expression in TCC of the bladder, with a trend towards low levels to be found more frequently in high-grade invasive TCC of the urinary bladder. However, despite encouraging in vitro and initial clinical findings, both the role of the MRP gene in clinical drug resistance and its role in the normal, non-neoplastic urothelium (and the consequence of variations in expression) still remain to be defined. The recent development of discriminatory anti-MRP monoclonal antibodies (Flens et al., 1994; Hipfner et al., 1994) should aid the progress of investigations regarding the relationship between MRP mRNA, protein levels/localisation and drug resistance in both tumour and cell line samples, and help to elucidate their significance in terms of tumour response to chemotherapy.
